drugset
drugset / Trial / NCT00674947

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

NCT00674947 ↗

Phase 1 Completed 55 enrolled Biogen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

Timeline

Start
2008-06
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB015 Monoclonal antibody — Intravenous

Indications

cancer